PhaseWell and BBH Forge Alliance to Boost Neuropsychiatric Trials

NASHVILLE, Tenn. – January 21, 2026 – In a strategic move to address the growing need for mental health and neurological treatments, national clinical research company PhaseWell Research has announced a significant partnership with Bio Behavioral Health (BBH), a specialized central nervous system (CNS) research site. The collaboration aims to expand patient access to critical neuropsychiatric clinical trials, combining PhaseWell's national scale with BBH's deep, community-based expertise.

This alliance reflects a broader trend of consolidation and specialization within the clinical trial industry, as research organizations seek to enhance efficiency and accelerate the development of next-generation therapeutics for some of medicine's most challenging conditions.

A Strategic Alliance for Innovation

PhaseWell Research, headquartered in Nashville, has been building a national network of high-performing research sites. The partnership with New Jersey-based Bio Behavioral Health significantly strengthens its capabilities in the complex and rapidly evolving field of neuropsychiatry.

“Partnering with Bio Behavioral Health aligns perfectly with our mission to expand access to complex clinical research in the community setting,” said Carsten Bick, Chief Executive Officer of PhaseWell Research, in a statement. “Neuropsychiatric disorders represent a critical and growing area of unmet need in the United States, but the medical science coming down the pike is potentially game-changing for this patient population. By combining PhaseWell’s national platform with BBH’s expertise and community reach within the therapeutic area, we are improving our position to increase patient access to this incredibly important next generation of therapeutics.”

For Bio Behavioral Health, a site with over 200 completed trials since its founding in 1987, the partnership offers an opportunity to amplify its impact. The organization has built a strong reputation for conducting Phase III and IV trials for conditions like depression, Alzheimer's disease, PTSD, and schizophrenia.

“Joining PhaseWell Research allows us to scale our impact while staying true to our mission of delivering compassionate, community-based neuropsychiatric research,” said Dr. Ashok Patel, founder and leading principal investigator at Bio Behavioral Health. “Together, we can broaden access to clinical trials for patients, strengthen partnerships with sponsors and CROs, and continue advancing high-quality research that meaningfully contributes to the advancement of medicine in our space.”

Tapping a Burgeoning Market

The timing of this partnership is critical, as it aligns with substantial growth in the mental health clinical trials market. Valued at approximately $3.17 billion in 2024, the market is projected to more than double to over $7 billion by 2034. This surge is fueled by the rising prevalence of mental health disorders, record venture funding for novel treatments, and expanding sponsor budgets for late-stage drug pipelines.

Depression research continues to dominate the field, but other areas like schizophrenia are expanding rapidly. The collaboration between PhaseWell and BBH positions the combined entity to effectively serve this demand. BBH brings decades of experience in a wide range of CNS indications, including Alzheimer's, Parkinson's, bipolar disorder, and ADHD, complementing PhaseWell's broader therapeutic portfolio which includes oncology and cardiovascular medicine. This specialized focus is crucial for pharmaceutical sponsors who require sites with proven recruitment strategies and the ability to generate high-integrity data in these sensitive patient populations.

Consolidation in a Competitive Field

PhaseWell's partnership with BBH is the latest step in a deliberate growth strategy backed by private equity firm Shore Capital Partners. PhaseWell was formed in August 2025 through an initial network that included Renstar Medical Research in Florida and Gabrail Cancer Center Research in Ohio, both established sites with decades of experience. The addition of BBH signals a clear intention to build a dominant, specialized network capable of competing with other major players like CNS Healthcare and Hassman Research Institute.

By acquiring and partnering with trusted, high-performing community practices, PhaseWell is creating a model that offers pharmaceutical sponsors a compelling alternative to working with a fragmented collection of individual sites. This strategy aims to streamline operations, accelerate study start-up times, and provide access to diverse patient populations across the country—key advantages in a competitive landscape where efficiency is paramount.

The combined entity boasts a formidable track record, with PhaseWell's network having completed over 1,800 clinical trials contributing to more than 150 approved therapies. This history provides sponsors with the confidence needed to place high-stakes neuropsychiatric trials with the network.

Community-Centric Research as a Catalyst for Change

At the heart of the partnership's potential is BBH's deeply integrated, community-based research model. For over three decades, Dr. Patel and his team have focused on patient-centric care, removing common barriers to trial participation. BBH offers free evaluations and provides all study-related treatments and medications at no cost, with no insurance required. This approach, often supplemented with compensation for time and travel, makes cutting-edge research accessible to a wider demographic.

This model is particularly vital in neuropsychiatric research, where stigma, cost, and access can be significant hurdles. By conducting trials within a trusted local setting, the partnership can enhance patient recruitment and retention, which are chronic challenges in the industry. The establishment of the Memory and Aging Center of New Jersey by Dr. Patel further exemplifies this commitment to providing specialized care and research opportunities directly to the community.

By integrating BBH's proven, patient-focused approach into PhaseWell's national infrastructure, the alliance is poised to create a more robust and efficient pipeline for neuropsychiatric drug development. This hybrid model, leveraging both community trust and corporate scale, could become a blueprint for accelerating the delivery of new mental health treatments to the patients who await them.